All In Biotech

Drug Trial Radar · NCT07753148

Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 in Patients With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

May 5, 2031

Study completion May 5, 2031

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation). The study is looking at: * What side effects the study drug might cause * How well the study drug works * How much of the study drug is in the blood at different times * If the body makes antibodies (proteins that attach to substances your body does not recognize) against the study drug; this may cause the study drug to not work as well. * What is the best dose of the study drug to treat CCUS and LR-MDS

Conditions

  • Clonal Cytopenia of Undetermined Significance (CCUS)
  • Low-Risk Myelodysplastic Syndrome (LR-MDS)

Interventions

  • REGN17235Drug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
  2. Severity of TEAEsTime frame: Up to 5 years
  3. Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 5 years
  4. Severity of SAEsTime frame: Up to 5 years

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Uz Ghent

    Ghent, Belgium · Recruiting

  • Algemeen Ziekenhuis (AZ) Delta

    Roeselare, Belgium · Recruiting

  • Kings College Hospital NHS Foundation Trust, King's College Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.